Global and United States Generic Drugs Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Generic Drugs Market Report & Forecast 2024-2034
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
Market Analysis and InsightsGlobal and United States Generic Drugs Market
This report focuses on global and United States Generic Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Generic Drugs revenue was US$ 313470 million in 2022 and is forecast to a readjusted size of US$ 551330 million by 2029 with a CAGR of 8.3% during the review period (2024-2034).
Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Global Generic Drugs Scope and Market Size
Generic Drugs market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Generic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For United States market, this report focuses on the Generic Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
Teva
Novartis
Viatris
Sun Pharmaceutical
Aspen Pharmacare
Fresenius Kabi
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO
Stada Arzneimittel
Bausch Health
Hikma
Torrent
Glenmark
Piramal Pharma
Sawai Pharmaceutical
Segment by Type
Oral
Injection
Other
Hospital Pharmacy
Retail Pharmacy
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Generic Drugs definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Generic Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Generic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Drugs revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Market Analysis and InsightsGlobal and United States Generic Drugs Market
This report focuses on global and United States Generic Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Generic Drugs revenue was US$ 313470 million in 2022 and is forecast to a readjusted size of US$ 551330 million by 2029 with a CAGR of 8.3% during the review period (2024-2034).
Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Global Generic Drugs Scope and Market Size
Generic Drugs market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Generic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For United States market, this report focuses on the Generic Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
By Company
Teva
Novartis
Viatris
Sun Pharmaceutical
Aspen Pharmacare
Fresenius Kabi
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO
Stada Arzneimittel
Bausch Health
Hikma
Torrent
Glenmark
Piramal Pharma
Sawai Pharmaceutical
Segment by Type
Oral
Injection
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Generic Drugs definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Generic Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Generic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Drugs revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions